Bioactivity | Sulfo-NHS-LC-LC-Biotin (Biotin-XX-SSE), a biotin reagent, is used to label the proteins exposed to the external leaflet of intact exosomes and contains a larger spacer arm between the biotin and amine reactive linker. The size of this linker helps to overcome steric hindrance and increases labeling efficiency at the crowded exosome surface[1][2]. |
Invitro | Biotinylation of exosome proteins: Two hundred micrograms of intact exosomes were mixed with 10 mM Sulfo-NHS-LC-LC-Biotin at room temperature for 30 min. Four conditions were taken into account during this experiment: (a) an excess of Sulfo-NHS-LC-LC-Biotin was used to favor a complete saturation of exposed lysine residues and potential N-terminus, (b) the presence of the sulfonate group in Sulfo-NHS-LC-LC-Biotin blocks the reagent from penetrating the exosomal membrane, (c) Sulfo-NHS-LC-LC-Biotin has an spacer arm of 30.5 angstroms which improves the biotinylation of proteins in their natural conformation, and (d) amino acids labeled with Sulfo-NHS-LC-LC-Biotin will have an increase in mass of 452 Da. After incubation, the excess of Sulfo-NHS-LC-LC-Biotin was removed using a 10 KDa MWCO filtration device[2].Rat aortic endothelial cells (RAEC) were surface modified in suspension with 1 mM Sulfo-NHS-LC-LC-biotin for 10 min, followed by pelleting and resuspension in PBS[3]. |
Name | Sulfo-NHS-LC-LC-Biotin |
CAS | 194041-66-2 |
Formula | C26H40N5NaO10S2 |
Molar Mass | 669.74 |
Transport | Room temperature in continental US; may vary elsewhere. |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Reference | [1]. Diaz G, et al. Changes in the Membrane-Associated Proteins of Exosomes Released from Human Macrophages after Mycobacterium tuberculosis Infection. Sci Rep. 2016 Nov 29;6:37975. [2]. Gabant G, et al. Assessment of solvent residues accessibility using three Sulfo-NHS-biotin reagents in parallel: application to footprint changes of a methyltransferase upon binding its substrate. J Mass Spectrom. 2008 Mar;43(3):360-70. [3]. Ilia Fishbein, et al. Post-Deployment Modifications of Stent with Endothelial Cells. CARDIOVASCULAR AND PULMONARY DISEASES, 24, SUPPLEMENT 1, S68, MAY 01, 2016. |